Stereotaxis, Inc.

Equities

STXS

US85916J4094

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 10:28:22 16/07/2024 pm IST 5-day change 1st Jan Change
2.07 USD +2.99% Intraday chart for Stereotaxis, Inc. +16.38% +17.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell Small Cap Comp Value Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell Small Cap Completeness Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 2000 Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 3000E Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 3000 Growth Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 2500 Value Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 3000 Value Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 2000 Value Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 3000E Growth Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 2000 Growth Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 2000 Dynamic Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell Microcap Value Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 2500 Growth Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell Small Cap Comp Growth Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 2500 Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 3000 Index CI
Stereotaxis, Inc.(NYSEAM:STXS) added to Russell 3000E Value Index CI
Stereotaxis' Robotic Navigation System Used to Treat First Patients MT
Stereotaxis, Inc. Announces the Successful Treatment of the First Heart Rhythm Patients by Penn Presbyterian Medical Center Utilizing the Advanced Genesis Robotic Magnetic Navigation System CI
Stereotaxis Receives CE Mark Recertification in EU MT
Transcript : Stereotaxis, Inc., Q1 2024 Earnings Call, May 13, 2024
Stereotaxis to Buy Access Point Technologies MT
Earnings Flash (STXS) STEREOTAXIS Reports Q1 Revenue $6.9M, vs. Street Est of $7.1M MT
Stereotaxis, Inc. Provides Revenue Guidance for the Full Year 2024 CI
Stereotaxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Chart Stereotaxis, Inc.
More charts
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.01 USD
Average target price
4.5 USD
Spread / Average Target
+123.88%
Consensus
  1. Stock Market
  2. Equities
  3. STXS Stock
  4. News Stereotaxis, Inc.
  5. Stereotaxis Says First Arrhythmia Patients Treated With Genesis Robotic System at Chicago Hospital